Listenly

What are the three major companies developing new treatments for hair loss and what are their distinct approaches?

Answered at 14:51 in Nvidia Buys Hugging Face for .9B & Pharma Companies are Bullish on Baldness · Morning Brew Daily

— questions searchable right now

What are the three major companies developing new treatments for hair loss and what are their distinct approaches?

Three biotech companies are taking radically different approaches to hair loss. Cosmo is developing Clascotarone to block DHT directly at the follicle level, with FDA approval likely within a year, while Veridermix is converting minoxidil into pill form and targeting both male and female pattern baldness—positioning itself to deliver the first approved female hair loss pill in the U.S. Absci is using artificial intelligence to design an injectable shot treatment, mirroring the success model of GLP-1 medications.

The timing is notable: with pattern hair loss affecting 80 million Americans —50 million men and 30 million women—and no new drugs approved in almost three decades, the market is primed for disruption. Each company's strategy reflects a different bet on what will work best: hormonal intervention, systemic pill delivery, or injectable precision.

Three distinct pathways to the same problem

Cosmo's hormonal blocking approach targets the root cause directly. Clascotarone works by preventing the hormone that triggers male pattern baldness from activating at the hair follicle itself, sidestepping systemic side effects. This mechanism-first strategy has regulatory traction, with the company signaling approval could arrive within the next year.

Veridermix's pill strategy is equally ambitious but clinically broader. The company is reformulating minoxidil—the active ingredient in topical Rogaine—as an oral medication. The real innovation: they're the only one of the three explicitly targeting both sexes, which would make their product the first-ever approved pill for female pattern hair loss in the United States if it reaches the market. Their stock jumped nearly 500% after going public in February 2024, signaling investor conviction in this dual-sex approach.

Absci represents the AI-native bet. Their injectable treatment was designed using artificial intelligence, following the cultural and market success of GLP-1 shots for weight loss and metabolic health. This frames pattern baldness as a chronic condition deserving a regular injection, rather than a daily pill or topical application—a significant shift in patient behavior and compliance.

Neal Freyman on Morning Brew DailyAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Three biotech companies are taking radically different approaches to hair loss.

Neal Freyman · Nvidia Buys Hugging Face for $12.9B & Pharma Companies are Bullish on Baldness · Morning Brew Daily · answer at 14:51

Key takeaways

  • The timing is notable: with pattern hair loss affecting 80 million Americans —50 million men and 30 million women—and no new drugs approved in almost three decades, the market is primed for disruption.
  • Cosmo's hormonal blocking approach targets the root cause directly.
  • Veridermix's pill strategy is equally ambitious but clinically broader.

The full answer · about 2 min

Three biotech companies are taking radically different approaches to hair loss. Cosmo is developing Clascotarone to block DHT directly at the follicle level, with FDA approval likely within a year, while Veridermix is converting minoxidil into pill form and targeting both male and female pattern baldness—positioning itself to deliver the first approved female hair loss pill in the U.S. Absci is using artificial intelligence to design an injectable shot treatment, mirroring the success model of GLP-1 medications.

The timing is notable: with pattern hair loss affecting 80 million Americans —50 million men and 30 million women—and no new drugs approved in almost three decades, the market is primed for disruption. Each company's strategy reflects a different bet on what will work best: hormonal intervention, systemic pill delivery, or injectable precision.

Three distinct pathways to the same problem

Cosmo's hormonal blocking approach targets the root cause directly. Clascotarone works by preventing the hormone that triggers male pattern baldness from activating at the hair follicle itself, sidestepping systemic side effects. This mechanism-first strategy has regulatory traction, with the company signaling approval could arrive within the next year.

Veridermix's pill strategy is equally ambitious but clinically broader. The company is reformulating minoxidil—the active ingredient in topical Rogaine—as an oral medication. The real innovation: they're the only one of the three explicitly targeting both sexes, which would make their product the first-ever approved pill for female pattern hair loss in the United States if it reaches the market. Their stock jumped nearly 500% after going public in February 2024, signaling investor conviction in this dual-sex approach.

Absci represents the AI-native bet. Their injectable treatment was designed using artificial intelligence, following the cultural and market success of GLP-1 shots for weight loss and metabolic health. This frames pattern baldness as a chronic condition deserving a regular injection, rather than a daily pill or topical application—a significant shift in patient behavior and compliance.

More answers from this episode

 ·  All answers from Morning Brew Daily →
—
—
0:00
0:00